WO2016093412A1 - Gelatin sponge containing phosphate buffer solution (pbs) or phosphate buffer and applied to transcatheter arterial chemoembolization, and method for preparing same - Google Patents

Gelatin sponge containing phosphate buffer solution (pbs) or phosphate buffer and applied to transcatheter arterial chemoembolization, and method for preparing same Download PDF

Info

Publication number
WO2016093412A1
WO2016093412A1 PCT/KR2014/012414 KR2014012414W WO2016093412A1 WO 2016093412 A1 WO2016093412 A1 WO 2016093412A1 KR 2014012414 W KR2014012414 W KR 2014012414W WO 2016093412 A1 WO2016093412 A1 WO 2016093412A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphate buffer
gelatin sponge
pbs
buffer solution
solution
Prior art date
Application number
PCT/KR2014/012414
Other languages
French (fr)
Korean (ko)
Inventor
손지우
Original Assignee
주식회사 에이치제이메디칼
주식회사 엔스메디칼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2014-0177234 priority Critical
Priority to KR20140177234 priority
Application filed by 주식회사 에이치제이메디칼, 주식회사 엔스메디칼 filed Critical 주식회사 에이치제이메디칼
Publication of WO2016093412A1 publication Critical patent/WO2016093412A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/36Surgical swabs, e.g. for absorbency or packing body cavities during surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying, e.g. spreading, media, e.g. remedies, on the human body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

The present invention relates to a gelatin sponge containing a phosphate buffer solution (PBS) or phosphate buffer and applied to transcatheter arterial chemoembolization, and a method for preparing the same and, more specifically, to a gelatin sponge containing a phosphate buffer solution (PBS) or phosphate buffer and applied to transcatheter arterial chemoembolization, and a method for preparing the same, wherein the method comprising: a step of immersing a gelatin sponge in a phosphate buffer solution (PBS) or phosphate buffer at 4-37°C for 3-12 hours; a step of freeze-drying the gelatin sponge, which is impregnated with the phosphate buffer solution (PBS) or phosphate buffer, at a temperature condition of -10°C to -35°C for 30 minutes to 16 hours; a step of pulverizing the freeze-dried gelatin sponge; a step of separating the pulverized gelatin sponge into sizes of 10-100 μm, 100-300 μm, 300-500 μm, and 500-700 μm, respectively, wherein, after the pulverized gelatin sponge is transferred to a hospital while being kept in disinfected vials, or in package containers in which the pulverized gelatin sponge is stored in any one of a phosphate buffer solution and a phosphate buffer, the pulverized gelatin sponge is bound to physiological saline, distilled water, and an anticancer agent, which are introduced thereto, to be used as a therapeutic agent for liver cancer.

Description

[Rule 26 correction 05.01.2015 under Article] of the phosphate buffer solution (PBS) or a phosphate buffer, a method for producing gelatin sponge and derivatives containing a (Phosphate Buffer) applied to the carotid artery chemical embolization

The present invention relates to a phosphate buffer solution (PBS) or a phosphate buffer, the gelatin sponge and a method comprising (Phosphate Buffer) applied to the carotid artery chemical embolization, more particularly, 4 ℃ ~ 37 ℃ phosphate buffer solution (PBS of ) or phosphate buffer (phosphate buffer), a gelatin sponge for 3 to an immersion for 12 hours and the process, wherein the ginseng salt buffer solution (PBS) or phosphate buffer (phosphate buffer) to precipitate the gelatin sponge to -10 ℃ ~ -35 ℃ a step of freeze-drying temperature from 30 minutes to 16 hours and in the steps of pulverizing the lyophilized gelatin sponge, wherein the pulverized gelatin sponge 10 ~ 100㎛, 100 ~ 300㎛, 300 ~ 500㎛, 500 ~ the gelatin sponge also pulverized with a size of each separate 700㎛ is then delivered to the hospital as a packaging container as in any of the conditions contained sterile vials or phosphate buffer solution, phosphate buffer solution, physiological saline, distilled water, and the anti-cancer As it will be bonded to each other input of the phosphate buffer solution (PBS) or a phosphate buffer, the gelatin sponge and a method comprising (Phosphate Buffer) applied to the carotid artery embolization chemical configured to be used as a liver cancer therapeutic agent.

Typically, liver (Hepatoma) is one of the most common cancers in the world, particularly generated much from men.

Leading cause of liver cancer is chronic hepatitis due to hepatitis and chronic hepatitis C virus according to the hepatitis virus B, and the result is cirrhosis of chronic hepatitis caused by these viruses and proceeds prolonged inflammation known to the liver occurs.

In addition, there is a chronic liver disease, including liver damage caused by toxins such as alcoholic liver disease, ah Playa toxin can all cause liver cancer.

Liver cancer is more important than what the early screening because very fast pace, how to remove cancerous tissue surgery, a method using the carotid artery chemical embolization (Transarterial Chemoembolzation), percutaneous ethanol injection (Percutaneous Ethanol Injection) for the treatment of liver cancer , but a way to kill cancer cells by using high-frequency coagulation therapy (Radiofrequency Thermal Ablation), etc. these methods are the size of the liver is too large or ineffective if the invasion is larger vessels or have a cancer spread to other organs there are drawbacks.

Then, the liver cancer therapy liver resection, a liver transplant, topical therapy (high frequency heat treatment, topical, alcohol injection), the method including, but in at least about 50% of the country HCC since the diagnosis in cirrhotic status stage or advanced advanced carotid Chemistry embolization, the target anticancer therapy. External investigations are also important, such as the role of radiation therapy in handy political treatment.

The handy part of the carotid artery embolization of chemical SCHNEIDER liver cancer treatment and a new carotid therapeutics of drug release microspheres liver cancer treatment with (drug-eluting microbead) method.

Here, the drug release microspheres 100 - 700㎛ size fine sphere and inde method of treating liver cancer using the hepatic artery as emboli substance bound to anti-cancer drugs in the form of a permanent embolic materials such Bead produced by traditional drug release microspheres polyvynil alcohol of the vessel cross-severe damage to the blood vessel increases the difficulty when it is blocked permanently trying to re-treatment with a chemical embolization high recurrence rate as liver cancer.

In this case, the microspheres without blood vessels between the hepatic damage was fine guyimyeon enemy that exploded after treatment of liver cancer can be blocked permanently try again if the hepatic artery chemical embolization using if relapse.

Therefore, without causing harm to the liver is an urgent need to develop effective special drug-eluting microspheres to the liver.

The present invention to solve the above gelatin sponge of the phosphate buffer solution in combination an anticancer drug to embolic materials using the hepatic artery as embolic materials to be applied to the carotid artery chemical embolization configured to be able to treat liver cancer in handy SCHNEIDER (PBS) or containing a phosphate buffer (phosphate buffer) relates to a gelatin sponge and its preparation method.

Of 4 ℃ ~ 37 ℃ in order to attain the object of the phosphate buffer solution (PBS) or phosphate buffer (Phosphate Buffer) for immersing the gelatin sponge for 3-12 hours step, the ginseng salt buffer solution (PBS) or phosphate to buffer (Phosphate buffer) the gelatin process for the 30 minutes and freeze-dried for 16 hours in -10 ℃ ~ -35 ℃ temperatures and sponge, and a step of pulverizing the lyophilized gelatin sponge, the crushed precipitate gelatin sponge the 10 ~ 100㎛, hospital 300㎛ ~ 100, 300 ~ 500㎛, after each separated into a size of 500 ~ 700㎛, packaging condition contained in any of the sterile vial, or a phosphate buffer solution, phosphate buffer solution and then passed to, contain a physiological saline solution, distilled water and the anticancer agent is added phosphate buffer solution (PBS) or phosphate buffer (phosphate buffer) applied to the carotid artery embolization chemical configured to be used as a liver cancer therapeutic agent as bonded to each other It relates to a gelatin sponge and its preparation method.

The invention is a microsphere that is decomposed by the body after a period of time when the injection between for the treatment of liver cancer a microsphere that is decomposed in the body, blocking the blood supply to and the vascularized tumor during this period localized manner to the tumor the drug release microspheres are constantly (drug delivery) delivering the drug to the tumor while degradation is characterized in that to reduce the side effects due to systemic blood flow inlet of the anticancer agent and increasing tumor response.

And, when need for repeat procedures to re-high incidence of liver cancer patients have to re-enforce the chemical embolization using drug-eluting microspheres effect.

1 is a work flow diagram illustrating the operation process of the present invention to maneuver enemy.

Figure 2 is a perspective view showing a main portion of the gelatin sponge of the present invention.

3 (a) is a perspective view showing the main portion of the gelatin sponge of the present invention, a state immersed in a phosphate buffer solution (PBS) to maneuver enemy.

3 (b) is a perspective view showing a state immersed in the main portion of the gelatin sponge phosphate buffer (Phosphate Buffer) of the present invention to maneuver enemy.

4 after the gelatin sponge is immersed in the main portion of the phosphate buffer solution (PBS) or phosphate buffer (Phosphate Buffer) of the present invention cooled, perspective view showing a state crushed to a powder.

Figure 5 is a perspective view of a state been put in the packing process, the vial bottle in a state of being crushed into powder, after the main portion of the gelatin sponge of the present invention cooled.

Figure 6 is a perspective view of a saline or distilled water and the anticancer agent bonded to a gelatin sponge stored in the vials of the present invention, concave state to maneuver enemy.

In the following a description will be given of an embodiment of the present invention will be fully self-of ordinary skill to be easily carried out in the pertaining the present invention with reference to the accompanying drawings art. However, the present invention may be embodied in many different forms, not limited to the embodiments set forth herein.

And, in order to clearly describe the present invention in the drawings it is regarded as was described in nature and not restrictive. Like reference numerals designate like elements throughout the specification.

In the specification, assuming that any part comprises any component, which is not to control the other components, there is no particular of stated are to be regarded to include other components.

First, the present invention is to form a phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) is contained gelatin (30) sponge 10 to be applied to the carotid artery chemical embolization, as shown in FIG. 2 and FIG. 3, 4 It is.

Here, the gelatin sponge 10 is impregnated with a phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃ be subjected to the step of immersion for 3 to 12 hours.

And freeze for 16 hours at 30 minutes to the above ginseng salt buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) to precipitate the gelatin sponge 10, the sub-zero temperatures -10 ℃ ~ -35 ℃ step of the water through the drying process, which exists 10% to 20% and,

Here, as still another operation step of the present invention are ginseng salt buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer), (30) the precipitated gelatin sponge 10, the sub-zero temperatures -10 ℃ ~ -35 ℃ as to proceed along the step of the presence of water 0-10% by the method of freeze-drying for 16 ~ 48 hours to working order.

Next, a process of pulverizing the lyophilized gelatin sponge 10 is in progress.

Further, the pulverized gelatin sponge 10 is net body (not shown) 10 and through the 100㎛, 300㎛ 100 ~, 300 ~ 500㎛, after each separated by a standard of 500 ~ 700㎛, sterile vials to be subjected to a step of capture processing package.

The present invention as described above can be then frozen by immersing the gelatin sponge (10) in phosphate buffer solution (20) or phosphate buffer (Phosphate Buffer) (30), after the grinding treatment with a drying operation, packaging.

On the other hand, by cutting the gelatin sponge (10) has not been freeze-treated with normalized state

Phosphate buffer solution of 4 ℃ ~ 37 ℃ (PBS) (20) or phosphate buffer (Phosphate Buffer) was immersed for 3 to 12 hours (30), may be combined with anti-cancer agents.

Then, the gelatin sponge 10 is crushed by each standard is then delivered to the hospital as a packaging container states contained in any of the sterile vial, or a phosphate buffer solution, phosphate buffer solution, physiological saline, distilled water, and an anticancer agent is added as bonded to each other which it will be used as a liver cancer therapeutic agent.

On the other hand, the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer), (30) the precipitated gelatin sponge 10, in addition to the dehumidification drying, nitrogen drying, cold drying, vacuum drying, air drying method method lyophilization of which one is also a configuration that can be dried.

That is, the present invention can treat liver cancer by using the hepatic artery as an embolic material to the gelatin embolic materials in combination with an anticancer drug as handy SCHNEIDER.

Further, as a microsphere that is decomposed by the body after a period of time when the injection between for the treatment of liver cancer and microspheres which decompose in the body, blocking the blood supply to and the vascularized tumor during this period the local method in tumor drug release microspheres as a decomposition can be continuously delivering a drug to a tumor (drug delivery) decrease the side effects due to systemic blood flow inlet of the anticancer agent and increasing tumor response.

And, when need for repeat procedures to re-high incidence of liver cancer patients can be re-enforced chemical embolization using drug-eluting microspheres.

If the step-by-step instructions as the operation process of the present invention made of the above construction as follows.

After In the gelatin sponge of the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃, and the first step of the immersion for 3 to 12 hours,

The ginseng salt buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) and freeze-dried 10% for the gelatin sponge precipitated in 30 in 30 minutes at minus -10 ℃ ~ -35 ℃ temperature 16 hours to the second step to have a moisture of 20% and,

And a third step of pulverizing the lyophilized gelatin sponge,

The pulverized gelatin sponge using the net body 10 ~ 100㎛, 100 ~ 300㎛, 300 ~ 500㎛, was separated into a size of 500 ~ 700㎛, a sterile vial or pulverized gelatin sponge is a phosphate buffer solution, a packaging condition contained in any of the phosphate buffer solution may be formed through the fourth step for delivery to the hospital.

Another working process of the present invention are as follows.

After In the gelatin sponge of the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃, and the first step of the immersion for 3 to 12 hours,

The ginseng salt buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) is lyophilized to 0% ~ 10 for 16 ~ 48 hours the precipitated gelatin sponge to minus -10 ℃ ~ -35 ℃ temperature a second step to have a% of moisture,

And a third step of pulverizing the lyophilized gelatin sponge,

The pulverized gelatin sponge using the net body 10 ~ 100㎛, 100 ~ 300㎛, 300 ~ 500㎛, was separated into a size of 500 ~ 700㎛, processing to put each in sterile vials or packaging, or milling the gelatine sponge may be formed through the fourth step for delivery to the hospital as a packaging container conditions contained in any of the phosphate buffer solution, phosphate buffer solution.

That is, the present invention can be obtained after freezing by immersion of the gelatin sponge of the phosphate buffer solution or a phosphate buffer (Phosphate Buffer) via a process as described above, after the grinding treatment and the drying operation, packaging products.

On the other hand, the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer), (30) the precipitated gelatin sponge 10, in addition to the dehumidification drying, nitrogen drying, cold drying, vacuum drying, air drying method method lyophilization of which one is also a configuration that can be dried.

Another working process of the present invention are as follows.

And work to cut into a standardized conditions the gelatin sponge is not frozen processed,

Immersed standardized gelatin sponge for 3 to 12 hours a phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃ then may be bonded to the anti-cancer agents.

Then, the gelatin sponge 10 is after the state of the packaging container contained in any of the sterile vial, or a phosphate buffer solution, phosphate buffer solution was delivered to the hospital, physiological saline, distilled water, and an anticancer agent is added coupled together pulverized by standard as it can be used as a liver cancer therapeutic agent.

The present invention as described above is in a microsphere that is decomposed by the body after a period of time when the injection between for the treatment of liver cancer a microsphere that is decomposed in the body, blocking the blood supply to and the vascularized tumor during this period tumor constantly (drug delivery) delivering the drug to the tumor as a drug release microspheres to local decomposition method has a feature capable of reducing the side effects due to systemic blood flow inlet of the anticancer agent and increasing tumor response.

And, when need for repeat procedures to re-high incidence of liver cancer patients have to re-enforce the chemical embolization using drug-eluting microspheres effect.

Description of the invention described above will be appreciated that is for illustrative purposes, One of ordinary skill in the art without changing the technical spirit or essential features of the present invention easily deformed is possible in other specific forms will be.

Thus the embodiments described above are only to be understood as illustrative and non-restrictive in every respect. For example, the components that are described in one-piece can be performed with the components, which is described as the embodiment may be distributed, as the degree of dispersion combined form.

The scope of the invention is the description becomes than indicated by the claims, which will be described later, to be construed as the meaning and scope, and all such modifications as derived from the equivalent concepts of the claims fall within the scope of the subject innovation.

Claims (6)

  1. Phosphate buffer solution applied to the carotid artery chemical embolization characterized in that the gelatin sponge 10 is dipped in a phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) to be coupled with cancer formation ( PBS) or the gelatin sponge containing a phosphate buffer (phosphate buffer).
  2. According to claim 1,
    To form a gelatin sponge (10) is immersed in the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30),
    After the gelatin sponge 10 has passed after the frozen, pulverized with a pulverizing process gelatin sponge 10 is in a hospital in the packaging container conditions contained in any of the sterile vial, or a phosphate buffer solution, phosphate buffer solution, physiological saline, distilled water, and the anticancer agent are as the input combined with each other containing a phosphate buffer solution (PBS) applied to the carotid artery chemical embolization characterized in that the configuration to be used as a liver cancer therapeutic agent or a phosphate buffer (phosphate buffer) gelatin sponge .
  3. According to claim 1,
    The phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer), (30) the precipitated gelatin sponge 10, in addition to how the freeze-dried dehumidification drying, nitrogen drying, cold drying, vacuum drying, any of the air drying method one is also the gelatin sponge containing phosphate buffer solution (PBS) or phosphate buffer (phosphate buffer) applied to the carotid artery embolization chemical being configured to be dried.
  4. The gelatin sponge with Sikkim normalized by cutting in a state the gelatin sponge is not frozen treatment of the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃ for 3-12 hours after the immersion, a solution containing a phosphate buffer (PBS) or phosphate buffer (phosphate buffer) to be applied to the configuration to be coupled to an anticancer agent which is characterized carotid chemical embolization gelatin sponge.
  5. After In the gelatin sponge of the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃, and the first step of the immersion for 3 to 12 hours,
    Ginseng salt buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) is freeze-dried for the precipitated gelatin sponge from 30 to -10 ℃ ~ -35 ℃ temperature conditions, 16 hours 10% to 20% in a second step to have a moisture
    And a third step of pulverizing the lyophilized gelatin sponge,
    Using said pulverized gelatin sponge net body 10 ~ 100㎛, 100 ~ 300㎛, 300 ~ 500㎛, was separated into a size of 500 ~ 700㎛, sterile vials or phosphate buffered solution, and any of phosphate buffer solution of the containing gelatin sponges phosphate buffer solution (PBS) or phosphate buffer (phosphate buffer) applied to the carotid artery chemical embolization characterized in that the configuration allows a packaging state contained in one can be made via a fourth step of passing the hospital method.
  6. After In the gelatin sponge of the phosphate buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) of 4 ℃ ~ 37 ℃, and the first step of the immersion for 3 to 12 hours,
    Ginseng salt buffer solution (PBS) (20) or phosphate buffer (Phosphate Buffer) (30) is frozen for 16 ~ 48 hours the precipitated gelatin sponge to -10 ℃ ~ -35 ℃ temperature drying conditions of 0% to 10% a second step to have a moisture
    And a third step of pulverizing the lyophilized gelatin sponge,
    Using said pulverized gelatin sponge net body 10 ~ 100㎛, 100 ~ 300㎛, 300 ~ 500㎛, was separated into a size of 500 ~ 700㎛, sterile vials or phosphate buffered solution, and any of phosphate buffer solution of the containing gelatin sponges phosphate buffer solution (PBS) or phosphate buffer (phosphate buffer) applied to the carotid artery chemical embolization characterized in that the configuration allows a packaging state contained in one can be made via a fourth step of passing the hospital method.
PCT/KR2014/012414 2014-12-10 2014-12-16 Gelatin sponge containing phosphate buffer solution (pbs) or phosphate buffer and applied to transcatheter arterial chemoembolization, and method for preparing same WO2016093412A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR10-2014-0177234 2014-12-10
KR20140177234 2014-12-10

Publications (1)

Publication Number Publication Date
WO2016093412A1 true WO2016093412A1 (en) 2016-06-16

Family

ID=56107578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/012414 WO2016093412A1 (en) 2014-12-10 2014-12-16 Gelatin sponge containing phosphate buffer solution (pbs) or phosphate buffer and applied to transcatheter arterial chemoembolization, and method for preparing same

Country Status (1)

Country Link
WO (1) WO2016093412A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030097620A (en) * 1993-07-19 2003-12-31 더 유니버시티 오브 브리티쉬 콜롬비아 Anti-angiogenic compositions, a stent coated with the anti-angiogenic compositions and a method for manufacturing the stent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030097620A (en) * 1993-07-19 2003-12-31 더 유니버시티 오브 브리티쉬 콜롬비아 Anti-angiogenic compositions, a stent coated with the anti-angiogenic compositions and a method for manufacturing the stent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAKER, STEVEN GERALD: "In Vitro Elution of Analgesic Medications from an Absorbable Gelatin Sponge", MICHIGAN STATE UNIVERSITY, MASTER'S THESIS, 2011 *
BANICH, JC ET AL.: "Chemoattraction of CD 34+ Progenitor Cells and Dendritic Cells to the Site of Tumor Excision as the First Step of an Immunotherapeutic Approach to Target Residual Tumor Cells", J. IMMUNOTHER., vol. 26, no. 1, January 2003 (2003-01-01), pages 31 - 40 *
SUN, WEI ET AL.: "Hemostatic Absorbable Gelatin Sponge Loaded with 5-fluorouracil for Treatment of Tumors", INT. J NANOMEDICINE, vol. 8, 2013, pages 1499 - 1506 *

Similar Documents

Publication Publication Date Title
Covey Combat orthopaedics: a view from the trenches
Franz et al. Guidelines to aid healing of acute wounds by decreasing impediments of healing
Chung et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial
Wang et al. Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres
JP4598827B2 (en) Active ingredient, in particular lysis / resealing method and apparatus for incorporating asparaginase or inositol hexaphosphate in red blood cells
Aboushwareb et al. A keratin biomaterial gel hemostat derived from human hair: evaluation in a rabbit model of lethal liver injury
Yang et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma
Burkatovskaya et al. Use of chitosan bandage to prevent fatal infections developing from highly contaminated wounds in mice
Koning et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors
US20060004189A1 (en) Compositions for treating wounds and processes for their preparation
JP6254094B2 (en) Methods of making and using placental tissue grafts and it crosslinking dehydration
Illingworth et al. How to Minimize Infection and Thereby Maximize Patient Outcomes in Total Joint Arthroplasty: A Multicenter ApproachAAOS Exhibit Selection
Reffelmann et al. Transplantation of neonatal cardiomyocytes after permanent coronary artery occlusion increases regional blood flow of infarcted myocardium
Jain et al. Engineered erythrocytes as a drug delivery system
Kheirabadi Evaluation of topical hemostatic agents for combat wound treatment
Korbelik et al. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
MX2010004508A (en) Delivery of active agents.
ES2393160T3 (en) Conservation of bioactive materials lyophilized foam
KR101157260B1 (en) Composition for chemoembolotherapy of solid tumors
Candilio et al. Protection of organs other than the heart by remote ischemic conditioning
US20090011032A1 (en) Methods for improved cryo-chemotherapy tissue ablation
Moore et al. Chemotherapy as an adjuvant to surgery
Öllinger et al. Role of heme oxygenase‐1 in transplantation
WO2000040269A2 (en) Pharmaceutical compositions for treatment of diseased tissues
Jenks et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-β in rodents and nonhuman primates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14907812

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/09/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 14907812

Country of ref document: EP

Kind code of ref document: A1